Concepedia

Acute Pulmonary Pressure Change After Transition to Sacubitril/Valsartan in Patients with Heart Failure Reduced Ejection Fraction

Jeffrey Tran, Ofer Havakuk, Jennifer M. McLeod, Jennifer Hwang, Hoi Yan Kwong, David M. Shavelle, Michael R. Zile, Uri Elkayam, Michael Fong, Luanda Grazette

ESC Heart Failure · 2021 · 28 citations · 12 references

Open access

Abstract

In this retrospective case series, transition from ACEI/ARB to sacubitril/valsartan was associated with an early and significant decrease in PAPs.

References

12

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

John J.V. McMurray, Milton Packer, Akshay S. Desai et al. · New England Journal of Medicine · 2014 · 6.6K citations · Full text

LCZ696, An Angiotensin Receptor–Neprilysin Inhibitor, Improves Cardiac Function with the Attenuation of Fibrosis in Heart Failure with Reduced Ejection Fraction in Streptozotocin-Induced Diabetic Mice

Yasunori Suematsu, Shin‐ichiro Miura, Masaki Goto et al. · European Journal of Heart Failure · 2016 · 154 citations · Full text

Ejection fraction improvement and reverse remodeling achieved with Sacubitril/Valsartan in heart failure with reduced ejection fraction patients.

Aws Almufleh, Jeffrey A. Marbach, Sharon Chih et al. · PubMed · 2017 · 114 citations · Full text

NPR-A–Deficient Mice Show Increased Susceptibility to Hypoxia-Induced Pulmonary Hypertension

Lan Zhao, Lü Long, Nicholas W. Morrell et al. · Circulation · 1999 · 83 citations · Full text

LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone

Hiroaki Kusaka, Daisuke Sueta, Nobutaka Koibuchi et al. · American Journal of Hypertension · 2015 · 72 citations · Full text